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Abstract 
Inflammatory conditions are associated with a variety of diseases and can significantly contribute to their 
pathophysiology. Neutrophils are recognised as key players in driving vascular inflammation and 
promoting inflammation resolution. As a result, neutrophils, and specifically their surface formyl peptide 
receptors (FPRs), are attractive targets for non-invasive visualization of inflammatory disease states and 
studying mechanistic details of the process. 
Methods: A small-molecule Formyl Peptide Receptor 2 (FPR2/ALX)-targeted compound was combined 
with two rhodamine-derived fluorescent tags to form firstly, a targeted probe (Rho-pip-C1) and secondly 
a targeted, pH-responsive probe (Rho-NH-C1) for in vivo applications. We tested internalization, toxicity 
and functional interactions with neutrophils in vitro for both compounds, as well as the fluorescence 
switching response of Rho-NH-C1 to neutrophil activation. Finally, in vivo imaging (fluorescent intravital 
microscopy [IVM]) and therapeutic efficacy studies were performed in an inflammatory mouse model.  
Results: In vitro studies showed that the compounds bound to human neutrophils via FPR2/ALX without 
causing internalisation at relevant concentrations. Additionally, the compounds did not cause toxicity or 
affect neutrophil functional responses (e.g. chemotaxis or transmigration). In vivo studies using IVM 
showed Rho-pip-C1 bound to activated neutrophils in a model of vascular inflammation. The pH-sensitive 
(“switchable”) version termed Rho-NH-C1 validated these findings, showing fluorescent activity only in 
inflammatory conditions. 
Conclusions: These results indicate a viable design of fluorescent probes that have the ability to detect 
inflammatory events by targeting activated neutrophils. 
Key words: Inflammation, neutrophils, formyl peptide receptors, small-molecule imaging probes, intravital 
microscopy 
Introduction 
Inflammation has been described as the “new 
cardiovascular risk factor” [1], playing a key role in 
the pathophysiology of a number of different diseases 
including myocardial infarction [2], stroke [3], sickle 
cell disease [4-6], rheumatoid arthritis [7] and cancer 
[8, 9]. Neutrophils are the most abundant leukocytes 
in the blood and are the first responders in the host’s 









acting as modulators of inflammation [10]. In order to 
observe neutrophils, it is necessary to design effective, 
non-invasive imaging probes that can identify areas of 
inflammation and to provide mechanistic insights into 
pharmacotherapy for diseases.  
Fluorescence microscopy is a well-established, 
pre-clinical tool which has high sensitivity and spatial 
resolution allowing biological systems and events, 
such as inflammation, to be investigated on a cellular 
and subcellular level [11-13]. Although the design of 
targeted fluorescent probes that enable the 
visualization of cells (e.g. neutrophils) are widely 
reported, they often have a number of drawbacks 
including large size, poor photostability and, in some 
cases, restricted labelling sites, in particular when 
using peptide-based targeting groups [14, 15], all of 
which makes them unsuitable as diagnostic tools.  
One particular target of current interest is the 
Formyl Peptide Receptors (FPRs). These 
seven-transmembrane G protein-coupled receptors 
(GPCR) are expressed on a variety of cells including 
neutrophils, with three receptors subtypes in the 
humans: FPR1, FPR2/ALX (termed the lipoxin 
receptor and previously known as Formyl Peptide 
Receptor-Like 1 (FPRL1)) and FPR3 (previously 
termed FPRL2), nomenclature detailed in reference 
[16] and shown in Table S1). FPR2/ALX in particular 
has been described as a key receptor involved in 
inflammation resolution [17-19] and an absence of the 
receptor has been shown to contribute to progressive 
disease states [20]. As a result, FPR2/ALX is an 
important target for biomedical research. 
Methods to track neutrophils via the FPR family 
have previously focussed on preparing imaging 
agents for magnetic resonance imaging (MRI) [21], 
positron emission tomography (PET) [22], optical [23] 
and single-photon emission computed tomography 
(SPECT) [24, 25] from synthetic modifications of 
peptide-based targeting units that were derived from 
the FPR1 antagonist cinnamoyl-F-(D)L-F-(D)L-F 
(cFLFLF) scaffold [26, 27]. These probes bind mainly 
via FPR1 and often suffer from poor target to 
background ratios as a result of the high 
hydrophobicity of cFLFLF, which necessitates 
incorporation of for instance, large, PEGylated chains. 
In addition, their preparation is expensive and 
peptide-based agents are thought to be less 
synthetically and metabolically robust than 
non-peptidic ligands [28]. Similarly, the potent 
pan-FPR agonist fMLF (formyl-Met-Leu-Phe) has 
been modified by solid state peptide synthesis 
strategies to prepare probes for both optical and 
radio-imaging [29-31] and a probe based on a peptidic 
FPR2/ALX agonist, WKYMVm, has been used in 
microscopy [32]. However, the risk with modifying 
potent receptor agonists to produce targeted imaging 
systems is the unwanted receptor activation that can 
occur. To circumvent these issues, a non-peptidic, 
FPR2/ALX agonist 4-butoxy-N-[2-(4-methoxy- 
phenyl)-4-oxo-1,4-dihydro-2H-quinazolin-3-yl]-benza
mide (Quin C1) has been reported to exhibit 
concentration dependent properties [33, 34]. The 
agonistic effect of Quin C1 on neutrophils is only 
observed at higher concentrations compared to 
previous peptide-based counterparts such as fMLF or 
CFLFLF[22, 35], and synthetic modifications on the 
Quin C1 amine are possible, making it an ideal target 
for probe design. 
Based on these findings, we have recently 
reported a combination of this small-molecule with 
metal complexes to provide long-lived luminescent 
signals for time-resolved detection in fixed cells and 
found that the compound was preferentially taken up 
in activated neutrophils [36]. However, these 
metal-based compounds were not applicable for in 
vivo applications due to high concentrations required 
for visualisation in a biological setting. In the current 
work, we have expanded these findings to develop, 
prepare and characterize a derivative of Quin C1 to 
form an FPR2/ALX-targeted imaging probe which 
can be used for tracking inflammation with high in 
vivo stability. For this purpose, a rhodamine B-derived 
fluorophore was chosen due to well-established 
compatibility with biological applications, high 
quantum yields, good stability and ease of synthetic 
modification [37]. Additionally, Rhodamine B dyes 
emit in the low energy visible region and as a result, 
provide a convenient compromise for preclinical 
imaging between providing the level of tissue 
penetration (i.e. long enough wavelengths) required 
for in vivo studies while at the same time maintaining 
some resistance to decomposition and photobleaching 
sensitivity compared to NIR dyes [38]. Via synthetic 
modifications, we sought to prepare one motif which 
excludes the possibility of rhodamine spirocyclisation 
[37] (which results in formation of a non-emissive 
species) to act as a probe for neutrophils under 
inflammatory conditions and constructed a second, 
“switchable” (pH-sensitive) analogue, which remains 
non-fluorescent under normal physiological 
conditions but switches “on” when neutrophils have 
been stimulated. We herein demonstrate the utility of 
Rho-pip-C1 as a probe to visualize acute 
inflammation via neutrophil targeting along with 
establishing a pH-sensitive probe which specifically 
“switches on” under inflammatory conditions. Thus, 
our novel probes enable the visualization of 
inflammation for biomedical research and a screening 
tool for drug discovery. 





Material and Methods  
Materials 
All commercially available reagents were bought 
from Sigma Aldrich (St-Louis, MO, USA) or Fisher 
Scientific (San Diego, CA, USA) unless otherwise 
stated. 
Drugs and antibodies 
Tumor necrosis factor-alpha (TNFα, 250 ng per 
200 µL) [39] R&D systems (Minneapolis, MN, USA) 
and BMS-470539 (20 mg/kg IP, Tocris Bioscience, 
Bristol, UK; batch No: 1A/156791) [40] were used for 
invivo studies. Vehicle, phosphate buffered saline 
(PBS, Life Technologies, Grand Island, NY, USA), 
Boc2 (10 µM) (N-tert-butoxycarbonyl-L-Phe-D-Leu- 
L-Phe-D-Leu-L-Phe, MP Biomedicals, Cambridge, 
UK) and WRW4 (10 µM) (Trp-Arg-Trp-Trp-Trp-Trp, 
EMD Biosciences Inc, San Diego, CA, USA) were used 
as FPR antagonists [41]. Phorbol myristate acetate 
(PMA, 100 µM) was used to stimulate neutrophils 
[42]. Leukotriene B4 (LTB4) (1 µM) was used as a 
chemoattractant for chemotaxis and transmigration 
assays.  
General synthetic procedures  
Deuterated solvents were bought from Goss 
Scientific. 1H-NMR and 13C-NMR spectra were 
recorded on a Bruker AMX-400 spectrometer at room 
temperature unless stated otherwise and fully 
assigned where possible using 2D correlation 
spectroscopy. Coupling constants are quoted in Hz 
and multiplicities are abbreviated as: s = singlet, d = 
doublet, t = triplet, m = multiplet and br = broad. 
Electrospray Time-of- Flight and MALDI mass spectra 
were obtained using a Waters LCT Premier. 
Thin-layer chromatography was conducted using 
pre-coated Silica gel 60, F254 plates with a thickness of 
0.2 nm. UV-vis absorption spectra were recorded on a 
Perkin Elmer 650 spectrometer and fluorescence 
spectra were obtained using a Varian Cary Eclipse 
spectrophotometer. For pH measurements a Jenway 
model 3510 pH/mV/temperature meter was used 
calibrated against pH 10.00, pH 7.00 and pH 4.00 
buffers. Column chromatography was performed 
using silica gel and laboratory grade solvents, under 
mild pressure. Synthetic and spectral details are given 
in the supplementary information.  
Animals  
Male C57BL/6 mice were purchased from 
Jackson Laboratory (Bar Harbor, ME) at 8-10 weeks of 
age (28-35 g). Mice were maintained on a 12 hours 
(h) light-dark cycle during which room temperature 
was maintained at 21–23 °C and had access to a 
standard chow pellet diet and tap water ad libitum. All 
animal experiments were approved by the Louisiana 
State University Health Sciences Center-Shreveport 
(LSUHSC-S) Institutional Animal Care and Use 
Committee (IACUC) and were in accordance with the 
guidelines of the American Physiological Society, or 
complied with ARRIVE (Animal Research: Reporting 
In Vivo Experiments) guidelines and followed the 
European Union Directive (2010/63/EU). All studies 
were performed blinded and randomized, with a key 
system to identify which animal/sample had 
undergone which treatment. Furthermore, 
compounds administered were made by laboratory 
personnel other than the one performing the 
experiment. 
Human samples 
The study was approved by the institutional 
review board of the LSUHSC-S (STUDY00000261) and 
conducted in accordance with the Declaration of 
Helsinki. After signed consent was obtained, blood 
was taken from control volunteers (23 – 65 years old. 
Eleven males, four females). Volunteers that were 
pregnant were excluded from the study. 
Neutrophil isolation and treatment 
Blood was collected from healthy volunteers 
after obtaining informed consent in 50 mL syringes 
that had already been filled with 5 mL acid citrate 
dextrose (ACD) solution. Blood was transferred 
evenly into two 50 mL tubes and spun at 1000 rpm for 
20 minutes at room temperature (with brakes at 6:6 to 
avoid neutrophil activation). The plasma layer was 
removed and blood was separated with a 
double-density gradient using 6% dextran (incubate 
for 15- 20 minutes and collect leukocyte layer), 
followed by Histopaque 1077 [43]. After 
centrifugation at 1500 rpm for 30 minutes, neutrophils 
were collected as a pellet and contaminating red 
blood cells were removed by osmotic lysis in ice-cold 
water. PMN cells were washed in PBS and 
re-suspended in Dulbecco’s modified Eagle’s medium 
(DMEM) with 3% fetal calf serum (FCS. Biochrome, 
Cambridge, UK).  
Ex vivo generation of murine neutrophils from 
Hoxb8 conditionally immortalized neutrophil 
progenitors  
The Hoxb8 neutrophil model was generated and 
used essentially as described [44]. In brief, 
Hoxb8-dependent neutrophil progenitors were 
generated by transducing progenitor cells enriched 
from C57BL/6 bone marrow single cell suspensions 
with a murine retroviral expression vector for the 
transcription factor Hoxb8 fused to the human 





estrogen receptor (Hoxb8-ER). The resulting 
immortalized line was kept in Optimem Glutamax 
medium (Fisher Scientific) supplemented with 100 
U/mL penicillin, and 0.1 mg/mL streptomycin, 30 
µM beta-mercaptoethanol, 10% fetal bovine serum 
(FBS) (Biochrome, Cambridge, UK), 20 ng/mL 
recombinant SCF (Immunotools, Friesoythe, 
Germany), and 1 µM beta-estradiol. Neutrophil 
differentiation was induced by estrogen withdrawal 
for 4 days and was monitored by flow cytometry for 
complete downregulation of c-Kit and CD34, and 
upregulation of CD11b and Ly6G. Cells were cultured 
at 37°C in in a 5% CO2 atmosphere. 
The human promyelocytic cell line HL-60 was 
cultivated in RPMI-VLE (Millipore, Burlington, MA, 
USA) supplemented with 1% L-glutamine, 1% 
non-essential amino acids, 100 U/mL penicillin, and 
0.1 mg/mL streptomycin, and 10% FBS and was 
induced to differentiate toward neutrophil–like cells 
for seven days via addition of 1.25% DMSO 
(Applichem, Darmstadt, Germany). Cells were 
cultured at 37 °C in a 5% CO2 atmosphere. Expression 
of FPR1 and FPR2 upon differentiation was confirmed 
by qPCR using the Quantitect (Qiagen, Hilden, 
Germany). HeLa cells stably expressing N-terminally 
FLAG-tagged human FPR1 or FPR2/ALX were 
cultured in DMEM and supplemented with 10% FBS, 
100 U/mL penicillin, and 0.1 mg/mL streptomycin. 
Cells were cultured at 37 °C in in a 5% CO2 
atmosphere. 
Cytotoxicity analysis 
Cells were treated with the indicated agonists for 
15 minutes at 37 °C and were then washed and 
resuspended in Cell Wash (BD Bioscience) containing 
50 nM of the cell-impermeant far-red emitting nucleic 
acid stain Helix NP NIR (Biolegend, San Diego, CA, 
USA) for detection of compromised cells. A Guava 
easyCyte™ System (Millipore, Burlington, MA, USA) 
was used to determine the percentage of Helix NP 
NIR-negative cells per 10,000 cells analysed. Triton 
X-100 (1%) was used as a positive control. 
Detection and quantification of reactive 
oxygen species (ROS) generation 
ROS production was measured by flow 
cytometry using dihydrorhodamine 123 (DHR123). 
Cells were preincubated for 20 minutes at 37 °C. The 
indicated agonists and DHR (2 µM) were then added 
for 15 minutes. To stop the reaction, cells were placed 
on ice, washed, and resuspended in Cell Wash (BD 
Bioscience) containing 0.5% PFA and 50 nM of the 
cell-impermeant far-red emitting nucleic acid stain 
Helix NP NIR (Biolegend) to gate for live cells. 10,000 
live cells per condition were analysed on a Guava 
easyCyte™ System (Millipore, Burlington, MA, USA) 
for median fluorescence intensity. Agonist-mediated 
ROS production was expressed as percentage of the 
signal detected in untreated cells. The FPR2/ALX 
specific agonist WKYMVm was used as a positive 
control. 
Chemotaxis assay 
For the chemotaxis assay, neutrophils were 
diluted to a concentration of 4 × 106 cells/mL in 
DMEM and 3% FCS and then treated with different 
concentrations (10-6 M to 10-9 M) of both the 
compounds for 10 minutes. The assay was performed 
using 3 μm pore size ChemoTx® System 96 well 
plates (Neuro Probe, Gaithersburg, MD USA) by 
adding 29 μL of 10-6 M LTB4 as a chemotactic stimulus 
or PBS as control to the bottom wells, and 25 μL of 
neutrophil-vehicle/compound suspension on top of 
the filter membrane. Plates were incubated for 3 hours 
at 37 °C with 5% CO2. After 3 hours the filter 
membrane was removed, and migrated cells were 
manually counted by taking 20 μL from the bottom 
wells and diluting in a 1:1 ratio with trypan blue. 
Results were expressed as an average of total number 
of cells in the bottom well from samples run in 
duplicates.  
Transmigration assay 
For the transmigration assay, neutrophils were 
diluted to the concentration of 1 × 106 cells/mL in 
DMEM with 3% FCS and then treated with different 
concentrations (10-6 M to 10-9 M) of the compounds for 
10 minutes. Prior to this step, 24-well plate inserts 
were treated with fibronectin for 30 minutes. Next, 
32,000 human umbilical vein endothelial cells 
(HUVECs) cells/200 μL were added and grown for 72 
hours to form a confluent monolayer. When the 
monolayer had formed, HUVEC media was removed 
and 500 μL of treated neutrophil-vehicle/compound 
suspension was added onto the inserts. In a fresh 
24-well plate 500 μL of PBS (control) or 
chemoattractant (10-6 M LTB4) were added and inserts 
were transferred to the plate. Plates were incubated 
for 3 hours at 37 °C with 5% CO2. After 3 hours the 
inserts were removed, and migrated cells were 
manually counted by taking 20 μL from the bottom 
wells and diluting in a 1:1 ratio with trypan blue. 
Results were expressed as total number of cells in the 
bottom well. 
Myeloperoxidase release assay (MPO) 
For the MPO release assay, three solutions were 
prepared; solution 1 consisted of KH2PO4 (5.4 g, 0.040 
mol), EDTA (1.875 g, 0.006 mol) and Triton-x-100 (5 
ml) at pH 5.4. Solution 2 was made up of 3,3’,5,5’- 
tetramethylbenzidine (TMB, 10 mM) prepared in 





acetone (2 ml) and solution 3 contained 30% H2O2 (25 
µl) in H2O (10 ml). The final MPO assay solution was 
prepared by combining solutions 1, 2 and 3 in the 
ratio of 9:1:0.1 respectively. Neutrophils (1x 105/well) 
were seeded in a 96 well plate and were treated with 
vehicle (PBS) or PMA for 3 hours at 37 oC, 5% CO2. In 
some cases, neutrophils were treated with different 
concentrations (10-6 M to 10-9 M) of the compounds for 
10 minutes prior to PMA stimulation for 3 hours.  
The neutrophil supernatant was collected from 
the 96 well plate (50 µl) and added to the well 
containing MPO solution (200 µl) (4:1 ratio), followed 
by incubation at room temperature until the color of 
the solution changed to blue. Addition of H2SO4 (25 
µl, 1 M) terminated the reaction and the absorbance 
was read at 450 nm and presented as an average from 
samples run in duplicates.  
Immunofluorescence microscopy 
Neutrophils (2 x 105 cells per well in 200 μL) 
were seeded on poly-L-lysine coated coverslips 
(Discovery Labware, Bedford, MA, USA) in a 24 well 
plate and either stimulated with PMA (100 nM) for 
one hour or treated with vehicle (1x PBS) at 370C, 5% 
CO2. Pharmacological blocking was carried out by 
waiting 30 minutes after seeding cells for 
equilibration before treating them with vehicle 
(saline), Boc2 (pan-FPR antagonist, 10 μM), or WRW4 
(FPR2/ALX antagonist, 10 μM) at 37 oC, 5% CO2 for 15 
minutes. The cells were then stained with Rho-pip-C1 
or Rho-NH-C1 (1 μM) for another hour and fixed in 
10% formalin. For cell identification, DNA was 
stained with the nuclear dye 4′,6-diamidino-2- 
phenylindole (DAPI; Molecular Probes, Eugene, OR, 
USA) in PBS for 10 minutes. After mounting 
(Fluoromont-G, Southern Biotech, Birmingham, 
Alabama, USA) the neutrophil-containing coverslips 
on glass slides, they were dried and firmly affixed 
using nail polish. The images were visualized using a 
Nikon Eclipse Ti inverted epifluorescence microscope 
(Minato-ku, Tokyo, Japan). In each experiment 
pictures were taken from three to four random fields 
with at least 30 cells per field of view [45]. Relative 
fluorescence intensities were then quantified from 
every image within each donor sample by calculating 
the ratio between emission intensity in the in-built 
Texas red channel to assess cell-associated 
Rho-pip-C1 (λexc = 595 nm/ λem = 645 nm and 
emission intensity in the in-built DAPI channel (λexc = 
356 nm/ λem = 460 nm) was used as a read-out for cell 
numbers using software on NIS Elements Advanced 
Research (Nikon Instruments Inc, Melville, NY, 
USA). The data was averaged to give the final results.  
Internalization Assays 
Flow cytometric analysis of receptor 
surface-associated immunofluorescence was used to 
determine agonist-induced internalization. Cells were 
left untreated or were incubated with Quin C1, or the 
derivatives Rho-pip-C1 and Rho-NH-C1 at the 
indicated concentrations for 15 minutes at 37 °C. 
W-peptide served as a positive control. Cells were 
incubated with 5 mM EDTA in PBS-/- for 3 minutes at 
37 °C and centrifuged at 200 x g for 5 minutes at 4 °C. 
To detect cell-surface accessible FLAG signal, cells 
were first incubated with ice-cold wash solution 
(PBS-/-, 5% BSA and 1 mM CaCl2) for 15 minutes on 
ice, followed by incubation for 45 minutes with 5 
µg/mL DyLight488 (Thermo Fischer Scientific, San 
Diego, CA, USA)-conjugated anti-FLAG M1 antibody 
on ice. Cells were washed twice in ice-cold cell wash 
solution (BD Bioscience). Median fluorescence 
intensity of 10,000 cells per condition was measured 
using a Guava easyCyte™ System (Millipore, 
Burlington, MA, USA). Far-red emitting Helix NP 
NIR (Biolegend, San Diego, CA, USA) was used to 
exclude compromised cells. Dylight 488-conjugated 
mouse IgG2 was used as an isotype control. 
Internalisation was measured via loss of cell surface 
signals in agonist-treated cells and was expressed as 
percentage of the signal detected in untreated 
samples. For each condition, at least six independent 
biological experiments were performed.  
Drug Treatment for Spinning Disc Intravital 
Microscopy imaging  
Saline or recombinant mouse TNFα (250 ng in 
200 µL saline) were injected via intrascrotal injection 2 
hours before cremaster surgical procedure [39]. A 
separate group of mice were treated with BMS-470539 
(20 mg/kg via intraperitoneal (i.p.) injection, 1 hour 
post TNFα injection [40]. No mortality occurred. 
Spinning Disc Intravital Microscopy 
Mice were anesthetized with ketamine 
hydrochloride (150 mg/kg body weight i.p. and 
xylazine (7.5 mg/kg body weight i.p.) and the jugular 
vein was cannulated for drugs/antibody 
administration). Rho-pip-C1 (15 µg in 50 µL of saline) 
was injected for recirculation one hour before 
leukocyte (neutrophil) observation. The cremaster 
muscle was prepared for intravital microscopic 
observation as previously described [46]. Body 
temperature was maintained at 35-37 °C. After a 20 
minute stabilization period, the cremasteric 
microcirculation was visualized using a spinning disc 
intravital microscope (an Olympus BX51WI upright 
microscope with a 40XW (LUMPLFLN) (Olympus, 
Center Valley, PA, USA) objective equipped with a 3i 





LaserStack laser launch (3i, Denver, CO, USA), 
Yokogawa CSU-X1-A1N-E spinning disk confocal 
unit (Yokogawa Electric Corporation, Musashino, 
Tokyo, Japan) and electron multiplier CCD camera 
(C9100-13; Hamamatsu, Bridgewater, NJ, USA)). 
Alexa Fluor 488 conjugated anti-mouse Ly-6G (Gr-1) 
clone RB6-8C5 (Biolegend, San Diego, CA, USA) (2 
µg/mouse) was used to identify neutrophils. 5-11 
venular segments (diameter 20-50 µm) were selected 
for evaluation and recorded. The number of adherent 
(stationary for ≥ 2 seconds) and extravasated (the 
number that had extravasated up to 50 μm either side 
of the 100 μm vessel length) neutrophils per vessel 
segment were measured and averaged for each 
animal. Data was analysed offline using Slidebook 
software (3i, Denver, CO, USA). 
Statistical Analysis 
All data was tested to follow a normal 
distribution using Kolmogorov-Smirnov test of 
normality with Dallal-Wilkinson-Lillie for corrected p 
value. Data that passed the normality assumption was 
analysed using Student’s t-test (two groups) or 
ANOVA with Bonferroni post-tests (more than two 
groups). Data that failed the normality assumption 
were analysed using the non-parametric 
Mann-Whitney U test (two groups) or Friedman with 
Dunn’s test (more than two groups). Analysis was 
performed using Graph Pad Prism 6.0 or 8.0 software 
(San Diego, USA). Data are shown as mean values ± 
standard error of the mean (SEM). Differences were 
considered statistically significant at a value of p < 
0.05. The figures have been graphically presented on a 
range-specific axis. All data and statistical analysis 
comply with Theranostics guidelines [47].  
Results  
Preparation of a small-molecule FPR2/ALX 
fluorescence probe (Rho-pip-C1). 
The FPR2/ALX targeting unit Quin C1 (6) [33], 
identified from an FPR2/ALX binding compound 
library screening hit, was prepared from 
commercially available 4-hydroxymethyl benzoate as 
previously reported (Figure 1) and combined with a 
fluorescent dye [36]. The dye of choice, a rhodamine B 
derivative, is known for a cyclisation equilibrium 
which is characterised by a closed, nonfluorescent 
spirolactam or lactone form, which is almost 
colourless [37, 48]. At low pH values, the carbonyl 
group becomes activated and a fluorescent, fully 
conjugated, ring-opened analogue is formed. This 
“switchable” property has been widely investigated 
in the sensing of heavy metal ions [49] and for 
preparation of pH-sensitive analytic probes [50].  
Initially, to prepare a non-switchable, fluorescent 
Quin C1-rhodamine conjugate, 1,4-piperazine-BOC 
was appended to rhodamine B (7) in a peptide 
coupling reaction to form a tertiary amine (8) and thus 
lock the rhodamine spirocyclic unit into its 
ring-opened, fluorescent state (see Figure 1 and 
Supplemental Material for synthetic procedures, 
Figures S1-4 LC chromatograms). Subsequent 
deprotection of the tert-butyl group, followed by 
addition of chloroacetyl chloride resulted in acylation 
of the secondary amine (10). Finally, Quin C1 was 
appended on the aromatic amine functional site to 
yield 11 (termed Rho-pip-C1). As expected, 
photophysical properties were not found to be 
significantly pH dependent and a strong, 
rhodamine-derived emission band at 582 nm was 
observed in methanol upon excitation at 350 nm, as 
well as overlapping, broad maxima at 403 nm, 428 nm 
and 453 nm (Figure S5). 
Rho-pip-C1 does not cause cytotoxicity  
Initially we examined the cytotoxicity of Quin C1 
and Rho-pip-C1 and Rho-NH-C1 in both human 
neutrophilic-differentiated HL60 cells and murine 
neutrophils produced from Hoxb8-dependent 
neutrophil progenitors. As shown in Figure S6 no 
cytotoxicity was observed for Quin C1 or Rho-pip-C1 
at the concentrations tested (10-6 M - 10-9 M), whereas 
the majority of the cells were compromised after 15 
minutes exposure to Triton X-100, included as a 
positive control. 
Rho-pip-C1 does not induce internalization of 
FPR2/ALX  
It is known that Quin C1 functions as a selective 
agonist for the FPR2/ALX[34]. G-protein coupled 
receptors (such as FPR2/ALX) rapidly internalize 
upon ligand binding, which is not advantageous in a 
tracer. However, Quin C1 elicits FPR2/ALX 
internalization only at concentrations above 1 µM 
[33]. To assess whether Rho-pip-C1 had any effect on 
receptor internalization, we examined whether the 
compound was able stimulate FPR2/ALX 
internalization using HeLa cells stably expressing 
N-terminally FLAG-tagged human FPR2/ALX [51]. 
Figure 2A shows that no significant changes in 
receptor internalization were observed over the 
chosen concentration range (10-6 to 10-9 M) between 
Quin C1 and Rho-pip-C1, supporting the concept that 
Rho-pip-C1 is a suitable imaging probe as ideal 
probes should not elicit internalization. 






Figure 1. Schematic of synthetic pathway for preparation of FPR2/ALX-targeted ligand (6) and the functionalised fluorescent probe (11, Rho-pip-C1). 
Reagents: i) 1-bromobutane, potassium carbonate, methanol, ii) hydrazine monohydrate, ethanol, iii) 2-nitro-benzoyl chloride, potassium carbonate, dichloromethane, iv) zinc 
dust, acetic acid, dichloromethane, v) 4-methoxy benzaldehyde, citric acid, ethanol, vi) tert-butyl piperazine-1-carboxylate, triethylamine, 
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate and dichloromethane, vii) trifluoroacetic acid, dichloromethane, viii) chloroacetyl chloride, 
triethylamine, dichloromethane ix) 6, N,N-diisopropylethylamine, acetonitrile. 
 
Rho-pip-C1 labels neutrophils via binding to 
FPR2/ALX 
To assess whether the Quin C1-derived probe 
Rho-pip-C1 could be used as a neutrophil label, 
neutrophils were isolated and incubated with 
Rho-pip-C1. As shown in Figure 2B and 2C, 
neutrophils incubated with Rho-pip-C1 displayed 
bright fluorescence labelling. These results were 
confirmed in a quantitative manner by measuring 
fluorescence emission intensities of cell-associated 
Rho-pip-C1 (Figure 2C). To verify whether 
Rho-pip-C1 was producing its fluorescence signal via 
the FPR family, neutrophils were treated with the 
pan-FPR antagonist Boc2 prior to Rho-pip-C1. Figure 
2D shows that blocking of the FPRs with the pan 
antagonist Boc2 induced a significant decrease (p < 
0.05) in the neutrophil-associated signal intensity. To 
further confirm whether the observed effects were 
specifically due to the actions of Rho-pip-C1 binding 
to FPR2/ALX, we repeated the experiments in the 
presence of the FPR2/ALX specific antagonist WRW4. 
Selective antagonism of neutrophil FPR2/ALX 
reduced the neutrophil Rho-pip-C1 signal intensity, 
confirming that Rho-pip-C1 binds to FPR2/ALX, 
similar to Quin C1 (a known FPR2/ALX agonist).  
Rho-pip-C1 does not alter the ability of 
neutrophils to perform their normal 
physiological functions 
An ideal imaging agent to detect neutrophilic 
inflammation should not only be able to bind with 
high affinity to the neutrophil, but also not alter the 
functional response of the cell. To investigate this, we 
tested the effect of Rho-pip-C1 on human neutrophil 
chemotaxis using a classic chemotaxis chamber. 
Figure 3A shows that vehicle-treated neutrophils 
were able to elicit a chemotactic response to 
leukotriene B4 (LTB4, 10-6 M) (0.62 ± 0.41 x 106/ml 
neutrophils vs. 2.79 ± 1.67 x 106/ml neutrophils, PBS 
vs. LTB4 respectively. p < 0.05). These responses were 
not altered by pre-treatment of neutrophils with 
varying concentrations (10-6 M, 10-7 M, 10-8 M and 10-9 
M) of Rho-pip-C1, suggesting that the imaging agent 
does not alter the functional ability of human 
neutrophils to move towards a chemical gradient.  






Figure 2. Rho-pip-C1 binds to FPR2/ALX, without causing receptor internalization. (A) Flow-cytometric analysis of FPR2 internalisation. HeLa cells stably expressing 
N-terminally FLAG-tagged human FPR2/ALX were used to determine whether Rho-pip-C1 and Rho-NH-C1 induce FPR2/ALX internalization at a concentration range of 10-6 to 
10-9M. Results are expressed as a loss of FPR2/ALX upon agonist treatment relative to untreated cells (100%). The lead compound Quin C1 was included for comparison. (B) 
Representative magnified images (100X) of fixed human neutrophils treated with Rho-pip-C1 and the nuclear stain DAPI (scale bar, 10 μM). (C) Representative 
immunofluorescence images from n = 5 independent donors in cells that had been treated with vehicle (PBS), the pan-FPR antagonist Boc2 (10 µM), or the FPR2 specific 
antagonist WRW4 prior to incubation with Rho-pip-C1 (scale bar, 100 μM). (D) Quantification of emission intensity ratios for vehicle (PBS), Boc2 (10 µM) and the FPR2/ALX 
specific antagonist WRW4 (10 µM) (n = 5 independent donors in each group). All imaging analysis was done in a double-blinded fashion. Statistical significance was determined 
using one-way ANOVA with Bonferroni post-hoc test and is presented as *p < 0.05 vs. PBS control. 
 
The ability of neutrophils to extravasate through 
an endothelial barrier forms a crucial part of the 
immune response [52]. Having determined that 
Rho-pip-C1 has no effect on neutrophil chemotaxis, 





we wanted to assess whether the same would hold 
true when neutrophils moved through an endothelial 
cell layer towards a chemoattractant. Figure 3B shows 
that neutrophils pre-treated with 10-7 or 10-8 M 
concentrations of Rho-pip-C1 were able to 
transmigrate through human umbilical vein 
endothelial cells (HUVEC) towards the LTB4 
chemoattractant, in a similar fashion to 
vehicle-treated neutrophils. We found a significant 
increase (p < 0.05) in the number of transmigrated 
neutrophils within the LTB4 groups compared to 
vehicle (1.60 ± 0.92 x 105/ml neutrophils vs. 5.74 ± 1.17 
x 105/ml neutrophils, PBS vs. LTB4 respectively. p < 
0.05. Figure 3B). These results suggest that at certain 
concentrations, Rho-pip-C1 does not affect the ability 
of the neutrophil to perform transmigration.  
Myeloperoxidase (MPO) is the most abundant 
pro-inflammatory enzyme stored in the azurophilic 
granules of neutrophils. Upon stimulation, 
neutrophils degranulate, releasing their MPO and 
thereby contributing to the inflammatory 
environment in a multitude of diseases [53]. 
Rho-pip-C1 had no effect on neutrophil chemotaxis at 
any concentrations tested and no effect on 
transmigration at certain concentrations tested (10-7 
and 10-8M), our final neutrophil functional response 
assay was to determine whether it had any effect on 
neutrophil degranulation. Figure 3C shows that all 
concentrations of Rho-pip-C1 did not alter the ability 
of neutrophils to produce MPO.  
Taken together our data suggest that Rho-pip-C1 
does not elicit any additional neutrophil functional 
responses upon binding to the receptor within the 
given concentration range and is thus a suitable 
candidate for in vivo tracking of neutrophils.  
Concentration dependent effect of Rho-pip-C1 
on neutrophil ROS production 
The generation of microbiocidal ROS from 
activated neutrophils plays an important role in 
antimicrobial host defence and inflammation. 
Interestingly, the FPR2/ALX agonist Quin C1 does 
not induce ROS [34] and might even display 
inhibitory properties [54], in line with a proposed 
anti-inflammatory function [34]. We assessed ROS 
levels in Hoxb8-derived murine neutrophils and 
human neutrophil-like differentiated HL60 cells 
stimulated for 15 minutes with the lead compound 
Quin C1 and Rho-pip-C1. Neither compound 
increased ROS production, whereas both cell types 
readily responded to control (WKYMVm) stimulation 
(Figure S7). 
Rho-pip-C1 is a robust fluorescent imaging 
agent for in vivo imaging of acute inflammation 
Next, we wanted to determine if Rho-pip-C1 
could be used effectively in a pre-clinical disease 
model of acute inflammation. Mice were injected with 
saline (vehicle control) or TNFα for two hours. Gr-1 
antibody conjugated with eFluor 488 fluorochrome 
was injected to label the neutrophil population within 
the cremasteric vasculature, as visualized using 
confocal intravital microscopy [37]. A cohort of mice 
were also treated with Rho-pip-C1. Neutrophils were 
identified using the Gr-1 antibody label. In saline 
treated mice (Figure 4A), there were significantly less 
neutrophils in the vessels labelled with Rho-pip-C1 
(i.e. Gr-1+/Rho-pip-C1+ cells) than neutrophils 
 
 
Figure 3. Rho-Pip-C 1 does not elicit changes in neutrophil function. (A) Neutrophils isolated from peripheral blood of healthy volunteers were resuspended in DMEM 
with 3% FBS and added at 100,000 cells on top of each chemotaxis filter. Neutrophil chemotaxis towards PBS (control) or LTB4 (10-6 M) using a chemotaxis plate after 3 hours 
was quantified by counting the neutrophils with Neubauer hemocytometer under bright field microscope. Some neutrophils were pre-treated with Rho-Pip-C1 at the indicated 
concentrations before chemotaxis (n = 5 independent donors in each group, with samples run in duplicate). (B) Quantification of transmigrated neutrophils through 
fibronectin-coated HUVECs. After 72 hours, human neutrophils were allowed to transmigrate through HUVECs for 3 hours towards PBS (vehicle) or LTB4 (10-6 M) and were 
counted using Neubauer hemocytometer. Some neutrophils were pre-treated with Rho-pip-C1 at the indicated concentrations before transmigration (n = 5 independent donors 
in each group). (C) Neutrophils were treated with vehicle (PBS) or phorbol 12-myristate 13-acetate (PMA) for 3 hours, with and without Rho-pip-C1 (10-6 M to 10-9 M). MPO 
levels were then quantified (n = 5 independent donors in each group, with samples run in duplicate) and statistical significance was determined using a one-way ANOVA with 
Bonferroni post-hoc test (A, C) or Friedman test followed by Dunn’s multiple comparison tests between groups (B) and is presented as *p < 0.05 vs. respective PBS control 
without chemoattractant. All experiments were done in a double-blinded fashion. 





labelled with just the Gr-1 antibody (Figure 4C, 3.95 ± 
1.14 Gr-1+ neutrophils vs. 0.69 ± 0.58 
Gr-1+/Rho-pip-C1+ neutrophils, p < 0.05), whereas no 
difference between Gr-1+/Rho-pip-C1+ and Gr-1+ 
neutrophils was observed in extravasated cells 
(Figure 4C). We also found that a few cells were 
labelled by Rho-pip-C1 but appeared not to be 
labelled by the Gr-1 antibody. These cells were 
Fpr2/ALX+ cells either with unknown origin, or more 
likely, neutrophils with a very weak Gr-1 signal. 
The effectiveness of Rho-pip-C1 as an imaging 
agent was further confirmed in the TNFα-induced 
inflammatory response group (Figure 4B), in which 
over 80% of neutrophils (Gr-1+) were also 
Rho-pip-C1+ (9.05 ± 1.42 Gr-1+ neutrophils vs. 7.47 ± 
1.37 Gr-1+/Rho-pip-C1+ neutrophils, Figure 4D). 
Collectively, these findings suggest that Rho-pip-C1 
labels neutrophils in an activated state and is an 
effective imaging agent to visualize inflammatory 
events. 
To further establish the identity of Rho-pip-C1 as 
an in vivo imaging agent, we treated a cohort of mice 
with the potent, selective melanocortin 1 (MC1) 
receptor agonist BMS-470539 [40]. Figure 4E shows 
that a reduction in the TNFα-induced inflammatory 
responses elicited BMS-470539 caused a decrease in 
the percentage of Rho-pip-C1 tagged neutrophils 
from 81.68 ± 2.92% to 20.69% ± 9.87% values which 
were comparable to those observed in the saline 
control (15.17 ± 5.04 %) [40]. The number of labelled, 
extravasated neutrophils was similar between the 
saline and TNFα treated mice (Figure 4F). 
Preparation of a pH sensitive analogue for 
imaging: Compound 13 (Rho-NH-C1) 
Having shown that Rho-pip-C1 could be used to 
image inflammation without changing the functional 
behavior of neutrophils, we next focused our efforts 
on developing a “switchable” version (i.e. pH 
sensitive) of the compound, which would only ‘turn 
on’ in low-pH environments (i.e. as observed in 
inflammation) [11, 55]. To achieve this goal, a 
rhodamine unit, that is found in its non-emissive 
spirocyclic form under neutral conditions, was 
attached to 6 via an ethylenediamine linker (Figure 
S8). Formation of the adduct Rho-NH-C1 was verified 
by HRMS and assessed by 1H- NMR and 13C- NMR 
(see Supplemental Material for synthetic procedures).  
A pH-dependent rhodamine emission and 
absorption profile was observed for Rho-NH-C1 in 
methanol/water (1:1 v/v) solutions. No 
rhodamine-centred emission was visible at 581 nm 
and at high pH (values above ~5). Increasing 
fluorescence and absorbance was observed as the pH 
value of the solution was decreased (Figure 5A+B). 
This effect was attributed to the amount of 
ring-opened form present in solution, with low pH 
values skewing the spirolactam equilibrium towards 
the open fluorescent state. The emission band 
observed at 457 nm for this compound showed no 
notable pH dependence. In order to determine the 
intramolecular spirocyclisation equilibrium constant a 
plot of normalised absorbance at 560 nm against pH 
value was fitted to a sigmoidal curve function (Figure 
5C). Using this method, the pH value at half the 
maximum absorbance was determined as pKcycl = 
3.97. Under normal physiological conditions (pH > 
5.5) the tag is expected to remain bound to 
neutrophils in a predominantly non-fluorescent state, 
as the rhodamine spirocyclic form prevails. In low pH 
environments, a fluorescent “on” response is 
triggered by an equilibrium shift towards the 
ring-opened rhodamine form resulting in an emission 
signal.  
In vitro assessment of fluorescence response to 
neutrophil activation 
As with Rho-pip-C1, we wanted to test the 
ability of Rho-NH-C1 to be an effective imaging agent 
by testing its effect on toxicity and neutrophil 
functional responses. Rho-NH-C1, as observed with 
Rho-pip-C1, did not have a toxic effect on HL60 cells 
or murine neutrophils at any of the concentrations 
tested (10-6 M - 10-9 M) (Figure S6). Chemotaxis and 
transmigration assays were performed in the presence 
of Rho-NH-C1. At 10-7 and 10-9 M Rho-NH-C1 elicited 
no change in neutrophil chemotactic behaviour, 
whereas all concentrations tested (i.e. 10-6 - 10-9 M) 
elicited no statistically significant alteration to 
neutrophil transmigration, rendering Rho-NH-C1 a 
useful tool for imaging acute inflammation (Figure 
S9). In addition, we also found that Rho-NH-C1 did 
not stimulate FPR2/ALX internalization. Figure 2B 
shows that Rho-NH-C1 shares a similar profile to that 
reported for the parent compound, Quin C1, 
supporting Rho-NH-C1 as a suitable imaging probe. 
Similarly, as with Rho-pip-C1, at certain 
concentrations (10-7 - 10-9 M), Rho-NH-C1 did not 
activate NADPH oxidase and subsequent superoxide 
production in human HL60 cells and murine Hoxb8 
neutrophils (Figure S7). 
“Switchable” Rho-NH-C1 is an effective tool 
for imaging inflammation  
Finally, to determine whether the “switchable” 
Rho-NH-C1 could be used in a physiological setting 
for imaging inflammation, human neutrophils were 
treated with vehicle (PBS) or PMA and incubated with 
Rho-NH-C1 or vehicle control. Figure 5D shows that 
unstimulated Rho-NH-C1 labelled neutrophils were 





not able to be visualized, although DAPI stain was 
clearly visible. In contrast, when the cells were treated 
with PMA, Rho-NH-C1-labelled neutrophils showed 
clear, rhodamine-based emission (Figure 5D). 
Emission intensity was quantified relative to DAPI 
(Figure 5E) and we demonstrated that the rhodamine- 
based emission intensity was increased in 
PMA-treated neutrophils vs. PBS-treated neutrophils 
(p < 0.05), implying that the “switchable” Rho-NH-C1 




Figure 4. Preferential uptake of Rho-Pip-C 1 on neutrophils in TNFα treated mice. Mice were treated with saline (control), TNFα (250 ng in 200 µL saline, 
intrascrotal injection) or TNFα+BMS-470539 (20 mg/kg via intraperitoneal injection). Confocal intravital microscopy was performed and mice were injected with Gr-1 antibody 
conjugated with eFluor 488 fluorochrome (green) and Rho-pip-C1 (red). Representative confocal intravital microscopy pictures of cremasteric vessels of (A) saline treated mice 
and (B)TNFα treated mice. Scale bar, 10 μM. Dotted line represents the edges of the vessel. The number of adherent (within) or extravasated (outside) neutrophils in the 
cremaster of (C) saline treated (control) (n = 5 mice per group) or (D) TNFα treated (n = 6 mice per group) mice was quantified. Mice were treated with saline (control), TNFα 
or TNFα+BMS-470539 and the number of (E) adherent (n = 5-6 mice per group) and (F) extravasated neutrophils (n = 5 mice per group) were quantified. Neutrophils were 
identified by their Gr-1 label and classified as either cells that were positive for Gr-1 (Gr-1+. Shown in green) or as cells that had taken up both Gr-1 and Rho-pip-C1 (Gr-1+/Rho+, 
dually labelled, shown in red), i.e. neutrophils that had taken up the probe. Statistical significance was determined using unpaired t-test, Mann-Whitney U test (C+D) or ANOVA 
with Bonferroni post-hoc test (E+F). $p < 0.05 vs. Gr-1; *p < 0.05 vs. saline control and #p < 0.05 vs. vehicle (saline) + TNFα control. All imaging analysis was done in a 
double-blinded fashion. 






Figure 5. “Switchable” Rho-NH-C1 is an effective tool imaging inflammation. (A) Emission spectra of 13 (Rho-NH-C1. 1 μM, 1:1 v/v methanol and water solutions) 
at varying pH values (λexc = 350 nm or λexc = 500 nm as indicated). (B) Absorption spectra of 13 (33 μM, 1:1 v/v methanol and water solutions) at varying pH values. (C) 
Determination of pKcycl value using the normalized absorption intensity at 500 nm and a sigmoidal fit (in-built OriginPro 2017 function). (D) Representative images of human 
neutrophils (n = 5 independent donors) that had been treated with vehicle (saline. Tops panels) and phorbol 12-myristate 13-acetate (PMA) (100 nM, bottom panels) prior to 
incubation with Rho-NH-C1 (scale bar, 100 μM). (E) Quantification of emission intensity ratios demonstrating a statistically significant difference between saline and PMA-treated 
human neutrophils (n = 5 independent donors in each group). Statistical significance was determined using unpaired t-test and is presented as *p < 0.05 vs. PBS control. All imaging 
analysis was done in a double-blinded fashion. 






Figure 6. Design and application of Rho-pip-c1 as a novel small molecule in-vivo imaging agent for acute inflammation. (A) Schematic of design elements in 
FPR2/ALX-targeted fluorescent probe, termed Rho-pip-C1. (B) Under non-inflammatory conditions (i.e. treatment with phosphate buffered saline (vehicle for tumor necrosis 
factor alpha [TNFα])), Rho-pip-c1 does not bind to FPR2/ALX on neutrophils, therefore no fluorescence is observed in the murine microcirculation using confocal intravital 
microscopy. (C) Acute inflammation is induced via injection of the pro-inflammatory cytokine TNFα. Rho-pip-C1 binds to FPR2/ALX on activated neutrophils and fluorescence 
can been observed and quantified using confocal intravital microscopy (recorded at λexc = 595 nm/ λem = 645 nm). 
 
Discussion 
Biological processes can be visualized both in 
vitro and in vivo using a variety of molecular imaging 
techniques [12, 56]. These techniques allow for their 
use in monitoring inflammatory disease states (such 
as tumour environments), for making clinical 
diagnoses and therapies as well as for biomedical 
research. Here we have prepared, characterized and 
tested in vitro and in vivo a novel FPR2/ALX-targeted 
small-molecule fluorescent imaging probe, termed 
Rho-pip-C1 (Figure 6), along with a “switchable” 
version, termed Rho-NH-C1 for pre-clinical 
inflammation tracking. 
Neutrophils are key players in both driving 
vascular inflammation and regulating its resolution, 
making them attractive targets for non-invasive 
visualisation of disease states. The FPR2/ALX 
receptor plays a central role in both promoting and 
resolving inflammation and can induce a variety of 
responses, making this receptor a particular target of 
interest in biomedical research. To this end, we 
designed a probe for neutrophil identification and 
imaging inflammation based on the small-molecule 
FPR2/ALX ligand motif Quin C1 [33], which we have 
previously demonstrated shows increased uptake in 
stimulated neutrophils [36]. Combination with a 
brightly fluorescent, rhodamine B- derived 





fluorophore, which are known for their high 
extinction coefficients and quantum yields as well as 
good biocompatibility, allowed us to prepare a 
fluorescent, FPR2/ALX-targeted probe.  
Using pharmacological blocking techniques with 
the aid of FPR pan antagonist Boc2, we found that 
Rho-pip-C1 binds to neutrophil FPRs to elicit its 
signal. This effect was replicated in the presence of the 
specific FPR2/ALX antagonist WRW4, suggesting an 
FPR (selectively FPR2/ALX) mechanism for the 
binding of Rho-pip-C1. In addition, we demonstrated 
that this binding of Rho-pip-C1 did not induce any 
changes in receptor internalization or alter neutrophil 
functional responses (as determined with the use of 
neutrophil functional assays). These results suggested 
the suitability of Rho-pip-C1 as an FPR2/ALX 
imaging probe.  
To evaluate these findings in a physiological 
setting we used an in vivo model of acute 
inflammation and examined whether our novel probe 
could be used to visualize key components of the 
inflammatory cascade i.e. neutrophil adhesion and 
extravasation. Using confocal intravital microscopy, 
we found ~80% of identified neutrophils were 
Rho-pip-C1 positive in the TNFα treated group, 
which was substantially higher than previously 
reported peptide-based FPR probes, where neutrophil 
labelling in vivo has been reported to be in the range of 
15% [27]. In the saline control group, only 15.17 ± 5.04 
% of observed neutrophils were tagged with Rho-pip 
C1. Thus, Rho-pip-C1 did not just simply act as a 
neutrophil tag, but also possesses the advantageous 
quality of preferentially tagging those neutrophils 
actively involved in the inflammatory cascade (a 
process characterised by vascular dilation, enhanced 
permeability of capillaries, increased blood flow and 
leukocyte recruitment, all of which could increase the 
uptake of the dye)[57]. These effects were further 
confirmed by the visualization and quantification of 
extravasated Rho-pip-C1+ neutrophils in both the 
saline and the TNFα group. Upon attenuation of the 
inflammatory response using BMS 470539, the 
number of labelled cells within the vessel was 
comparable to what was observed in the saline control 
group, whereas extravasated neutrophils were 
Rho-pip-C1 labelled. These results suggest that 
Rho-pip-C1 could be used as an imaging agent to 
successfully quantify the effect of an 
anti-inflammatory drug for drug discovery 
programmes. 
Inflammation is known to be associated with a 
lowered local extracellular pH range and the resulting 
acidification is central in the regulation of neutrophil 
functions [11, 55]. Accordingly, sensors that are bound 
to neutrophils in a non-fluorescent state and only 
selectively flag up neutrophils as they enter into an 
acidic environment through a fluorescent “on” 
response have the advantage that their switchable 
signal could relay valuable, real-time readouts on 
inflammatory status and cellular activity. Therefore, a 
pH-responsive rhodamine form was combined with 
Quin C1 to afford Rho-NH-C1. Our novel probe was 
deemed to be almost non-fluorescent at neutrophil pH 
and highly fluorescent at acidic pH, as determined by 
the emission intensity increasing as the pH was 
decreased. These effects were further confirmed by 
the ability of Rho-NH-C1 to produce a fluorescent 
signal with PMA-activated neutrophils, but not 
neutrophils treated with the vehicle, in which the 
rhodamine unit remained in a non-fluorescent state. 
Future studies will determine whether Rho-NH-C1 
and/or Rho-pip-C1 may act as an ago-allosteric 
modulator of FPR2/ALX in a similar fashion to the 
parent compound Quin C1. 
Conclusion 
We have developed a novel small molecule 
FPR2/ALX imaging probe which lacks the 
complications associated with previous FPR imaging 
probes (i.e. target cell internalization and activation) 
and binds to activated neutrophils (i.e. those involved 
in the activation of the inflammatory cascade), 
thereby differentiating it from previous FPR-probes. 
Additionally, simple synthetic modifications enabled 
us to capitalize on our imaging probe and make a 
“switchable” analogue (Rho-NH-C1), providing a 
promising basis as a sensor of inflammation for 
biomedical research and a screening tool for drug 
discovery. 
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